- Home
- IVZ vs JAZZ Comparison
IVZ vs JAZZ Comparison
Compare IVZ & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IVZ | JAZZ |
|---|---|---|
| Founded | 1935 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.9B | 16.1B |
| IPO Year | 2014 | 2007 |
Fundamental Metrics
Financial Performance| Metric | IVZ | JAZZ |
|---|---|---|
| Price | $30.74 | $242.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 14 |
| Target Price | $27.43 | ★ $217.57 |
| AVG Volume (30 Days) | ★ 3.1M | 869.5K |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.35% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 1.27 | ★ 7.17 |
| Revenue | ★ $5,314,100,000.00 | $1,618,693,000.00 |
| Revenue This Year | N/A | $6.22 |
| Revenue Next Year | $5.83 | $7.68 |
| P/E Ratio | ★ $24.24 | $33.59 |
| Revenue Growth | ★ 2.98 | N/A |
| 52 Week Low | $20.67 | $124.50 |
| 52 Week High | $33.66 | $266.38 |
Technical Indicators
Market Signals| Indicator | IVZ | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 41.76 | 43.33 |
| Support Level | $25.12 | $240.63 |
| Resistance Level | $31.02 | $242.66 |
| Average True Range (ATR) | 0.87 | 6.58 |
| MACD | -0.27 | -0.68 |
| Stochastic Oscillator | 5.26 | 20.27 |
Price Performance
Historical ComparisonAbout IVZ Invesco Ltd
Invesco provides investment management services to retail (69% of managed assets) and institutional (31%) clients. At the end of May 2026, the firm had $2.454 trillion in assets under management spread among its equity (61% of AUM), balanced (3%), fixed-income (21%), alternative investment (6%), and money market (9%) operations. Passive products account for close to half of Invesco's total AUM. Invesco's US retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside of North America, with 32% of its AUM sourced from Europe, Africa, and the Middle East (17%) and Asia (15%).
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.